GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Sponsored by the Trade Commission of Spain

The biotechnology industry in Spain has grown rapidly over the last decade. The country's life science business and academic sectors are major European players in carrying out R&D, creating spin-offs, and engaging in a wide range of collaborations. Spain is particularly accomplished in biomedicine. During this week's Podcast, Dr. José María Fernández Sousa-Faro discusses the current state of biotechnology in Spain and the country's plans for growing the bioindustry well into the future. He describes the activities of some of the key members of the Spanish Association of Bioenterprises and talks about the research and product development efforts of the biotech companies belonging to the Zeltia Group. Dr. Fernandez also details the most important strengths of the biotech industry in Spain and lists a few of the roadblocks that need to be overcome before the Spanish bioindustry can reach its full potential.

Dr. José María Fernández Sousa-Faro is President of the Spanish Association of Bioenterprises (ASEBIO), and Chairman of the Zeltia Group


Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?